ArticleAmerican journal of translational research2026
Development of a clinical indicator-based severity scoring system for pediatric atopic dermatitis and evaluation of dupilumab treatment outcomes.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo develop and validate a pediatric atopic dermatitis (AD) severity scoring system based on routinely available clinical indicators and to evaluate the efficacy and safety of dupilumab in children with moderate-to-severe AD.
methodsClinical data from 236 children with AD treated between January 2023 and January 2025 were retrospectively analyzed and randomly split into training and internal validation cohorts (7:3). An external validation cohort included 42 patients treated between February and June 2025. AD severity was classified using the SCORAD index. Factors associated with disease severity were identified by logistic regression, and a scoring system was developed and evaluated using receiver operating characteristic (ROC) and calibration curves. In addition, children with moderate-to-severe AD treated with dupilumab were assessed for changes in clinical scores at baseline and weeks 4, 12, and 16, with adverse events recorded.
resultsThe scoring system (0-9 points) included onset age ≤2 years, xerosis, spiny lichen, vitamin D insufficiency/deficiency, and eosinophil count ≥0.455×10
conclusionsA simple and practical severity scoring system for pediatric AD was developed and validated. Dupilumab demonstrated favorable efficacy and acceptable safety in children with moderate-to-severe AD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.